TUSTIN, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical stage products for the treatment of hepatitis C virus infection and cancer, today announced that senior management will present at the 2006 Biotechnology Industry Organization (BIO) InvestorForum on Thursday, October 19, 2006 at 11:40 am PDT, or 2:40 pm EDT. The presentation will be held in the Twin Peaks North Room at The Palace Hotel in San Francisco, CA.
Peregrine CEO and president Steven W. King will provide a review of recent corporate developments.
Mr. King’s presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.peregrineinc.com. A replay will be available on the Peregrine website and archived for approximately 90 days.
For more information about this conference, please visit: http://investorforum.bio.org/opencms/bif/2006/index.jsp.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing five separate clinical trials in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R) in the U.S. and India. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Contacts: GendeLLindheim BioCom Partners Investors Media info@peregrineinc.com Barbara Lindheim (800) 987-8256 (212) 918-4650
Peregrine Pharmaceuticals, Inc.
CONTACT: Investors, +1-800-987-8256, info@peregrineinc.com, or Media,Barbara Lindheim, +1-212-918-4650, both of GendeLLindheim BioCom Partners,for Peregrine Pharmaceuticals, Inc.
Web site: http://www.peregrineinc.com//
